Gabriel M Mbalaviele

60308362, Feb 29, 2000

Jun 8, 1999

9/327840

Mark A. Thiede - Forest Hill MD
Mark F. Pittenger - Severna Park MD
Gabriel Mbalaviele - Columbia MD

Osiris Therapeutics, Inc. - Baltimore MD

C12N 508
C12N 510

435347

The present invention is directed to human mesenchymal stem cells isolated from a tissue specimen, such as marrow cells, and to the method of co-culturing isolated mesenchymal stem cells and/or mesenchymal stem cell-derived adipocytes with hematopoietic progenitor cells such that the hematopoietic stem cells retain their phenotype.

62551124, Jul 3, 2001

Jun 8, 1999

9/327796

Mark A. Thiede - Forest Hill MD
Gabriel Mbalaviele - Columbia MD

Osiris Therapeutics, Inc. - Baltimore MD

C12N 506
C12N 516

435440

The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.

62391577, May 29, 2001

Sep 10, 1999

9/393434

Gabriel Mbalaviele - Columbia MD

Osiris Therapeutics, Inc. - Baltimore MD

A01N 4378

514369

A method for inhibiting the differentiation of CD34+ cells into osteoclasts by treating the cells with a peroxisome proliferator-activated receptor-. gamma. agonist.